why choose us

First received: December 06, 2022

Clinical Trial: Janus Kinase Inhibition in Granuloma Annulare

Study Status: Completed

Recruit Status: RECRUITING

Condition: Granuloma Annulare

Study Type: INTERVENTIONAL


Official Title: JAK1 Inhibition in Granuloma Annulare: an Opportunity for Pathogenesis Directed Therapy

Brief Summary: The primary objective is to determine if JAK1 specific inhibition is effective in treating granuloma annulare (GA), a problematic inflammatory skin disease without an FDA approved treatment.The primary outcome will be the percentage change in the body surface area (BSA) involvement by GA after 6 months of treatment with abrocitinib 200 mg daily in 10 patients with moderate to severe GA affecting at least 5% body surface area (BSA).

Read more